Exploring 3 High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has remained flat, but it is up 19% over the past year with earnings expected to grow by 17% per annum over the next few years. In this context of steady growth and optimistic projections, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and potential for expansion in a dynamic industry landscape.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 21.54% | 21.27% | ★★★★★★ |
| Fabrinet | 20.12% | 22.27% | ★★★★★★ |
| Coherent | 29.33% | 41.75% | ★★★★★★ |
| Lumentum Holdings | 40.65% | 104.45% | ★★★★★★ |
| Marker Therapeutics | 67.79% | 25.34% | ★★★★★★ |
| Insmed | 32.21% | 66.88% | ★★★★★★ |
| Madrigal Pharmaceuticals | 27.97% | 63.67% | ★★★★★★ |
| Syndax Pharmaceuticals | 29.10% | 69.45% | ★★★★★★ |
| Travere Therapeutics | 24.05% | 53.11% | ★★★★★★ |
| Precigen | 34.82% | 55.42% | ★★★★★★ |
Click here to see the full list of 22 stocks from our US High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Ardelyx (ARDX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines to address unmet medical needs globally, with a market cap of $1.01 billion.
Operations: Ardelyx generates revenue primarily through the development and commercialization of biopharmaceutical products, amounting to $450.89 million.
Ardelyx has demonstrated resilience and adaptability in a competitive biotech landscape, evidenced by its 24% annual revenue growth which outpaces the US market average of 13%. Despite recent executive changes, with Eric Foster stepping down as Chief Commercial Officer, the company remains poised for potential profitability within three years. This forecast aligns with their strategic filings like the recent $36 million Shelf Registration aimed at bolstering their financial flexibility. Ardelyx's commitment to innovation is further underscored by robust R&D investments that are integral to its growth trajectory in developing novel treatments.
- Delve into the full analysis health report here for a deeper understanding of Ardelyx.
Evaluate Ardelyx's historical performance by accessing our past performance report.
Madrigal Pharmaceuticals (MDGL)
Simply Wall St Growth Rating: ★★★★★★
Overview: Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) in the United States, with a market capitalization of approximately $12.11 billion.
Operations: Madrigal Pharmaceuticals focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the U.S., generating $1.28 billion from this segment.
Madrigal Pharmaceuticals, with a projected annual revenue growth of 28% and earnings forecast to surge by 63.67% per year, is setting a brisk pace in the biotech sector. The firm's recent appointment of Dr. John C. Reed to its board underscores its commitment to innovation, especially in R&D where it faces significant unmet medical needs across various therapeutic areas. Despite current unprofitability, Madrigal's strategic moves—including a substantial $717 million shelf registration—position it for potential profitability within three years, aligning with industry benchmarks that predict robust future performance for companies deeply invested in R&D and novel treatments development.
- Get an in-depth perspective on Madrigal Pharmaceuticals' performance by reading our health report here.
Learn about Madrigal Pharmaceuticals' historical performance.
Syndax Pharmaceuticals (SNDX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing cancer therapies, with a market capitalization of approximately $1.77 billion.
Operations: Syndax Pharmaceuticals generates revenue primarily from its biotechnology segment, specifically focusing on startups, with reported earnings of $252.25 million.
Syndax Pharmaceuticals is navigating a transformative phase with a projected revenue growth of 29.1% annually, outpacing the US market average of 13%. Despite current unprofitability, the company's strategic emphasis on R&D is evident as it moves towards profitability within three years, supported by an expected earnings growth of 69.45% per year. Recent events underscore its challenges and adaptability; notably, Syndax terminated a major license agreement impacting its operations in China but continues to progress in clinical developments with promising drug candidates like SNDX-4321 for NSCLC and SNDX-62122 for MF. These initiatives reflect its commitment to addressing unmet medical needs through innovative therapies.
- Click here and access our complete health analysis report to understand the dynamics of Syndax Pharmaceuticals.
Understand Syndax Pharmaceuticals' track record by examining our Past report.
Where To Now?
- Take a closer look at our US High Growth Tech and AI Stocks list of 22 companies by clicking here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com